Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia.

The authors discuss research which investigated the effectiveness of combined sorafenib and low-dose cytarabine (LDAC) in treating elderly patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS), conducted by D. Macdonald and colleagues, published within the issue. Topics explored include the sorafenib and LDAC dosage administered to patients involved in the study, the patients' response to treatment, and adverse events recorded.